New Delhi: Alembic Pharmaceuticals Limited has said that it has received final approval from the United States Food and Drug Administration (USFDA) for its supplemental Abbreviated New Drug Application (sANDA) for Paroxetine Extended-Release Tablets USP, 12.5 mg, marking another addition to its expanding portfolio in the United States generics market.
The approved formulation is therapeutically equivalent to the reference listed drug Paxil CR Tablets (12.5 mg), marketed by Apotex Inc.. Paroxetine, a widely prescribed antidepressant, is indicated for the treatment of several psychiatric conditions, including major depressive disorder, panic disorder, social anxiety disorder and premenstrual dysphoric disorder, the company said in a statement here.
Industry observers note that the approval is significant as it strengthens Alembic’s presence in the competitive U.S. generics space, where regulatory clearances are closely tied to market access and growth. The extended-release formulation, in particular, is designed to improve patient compliance by ensuring sustained drug release, thereby reducing dosing frequency.
With this latest approval, Alembic’s cumulative tally of approvals from the USFDA has reached 235, comprising 216 final approvals and 19 tentative approvals. The company’s growing pipeline reflects its sustained focus on regulated markets, especially the United States, which remains a key revenue driver for Indian pharmaceutical exporters, said the pharma firm.
Experts say that such approvals are critical for Indian pharmaceutical firms seeking to consolidate their position in global markets. The US generics market, while lucrative, is also highly regulated and competitive, requiring companies to demonstrate both product efficacy and manufacturing reliability.
The latest approval comes at a time when demand for affordable mental health medications is rising globally. Conditions such as depression and anxiety disorders are increasingly being recognised as major contributors to the global disease burden, driving the need for accessible and cost-effective treatment options.
By expanding its range of psychiatric medications, Alembic is positioned to tap into this growing demand while reinforcing its role in improving access to essential therapies.
The development is also indicative of the broader trajectory of the Indian pharmaceutical industry, which continues to play a pivotal role in supplying generic medicines worldwide. As companies like Alembic scale up their capabilities and secure regulatory approvals, their contribution to global healthcare access is expected to deepen further.
#alembicpharmaceuticalslimited #pharmaceuticals #health #mentalhealth #usfda
For more information, kindly contact indiahealthbuddy@gmail.com
